Complete Pathological Response After Neoadjuvant Chemo-Immunotherapy in Malignant Pleural Mesothelioma

被引：3
作者：
Tostes, Francinne T. [1 ]
Zugman, Miguel [1 ]
Paes, Vitor R. [1 ]
Schvartsman, Gustavo [1 ]
机构：
[1] Hosp Israelita Albert Einstein, Ctr Oncol & Hematol Einstein Familia Dayan Daycova, Sao Paulo, Brazil
来源：
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词：
mesothelioma malignant; chemo-immunotherapy combinations; checkpoint inhibition therapy; complete pathologic response (pCR); pleural mesothelioma; EXTRAPLEURAL PNEUMONECTOMY; MULTICENTER; TRIAL; CHEMOTHERAPY;
D O I：
10.3389/fonc.2022.836751
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页数：5
相关论文
共 8 条
  • [1] First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
    Baas, Paul
    Scherpereel, Arnaud
    Nowak, Anna K.
    Fujimoto, Nobukazu
    Peters, Solange
    Tsao, Anne S.
    Mansfield, Aaron S.
    Popat, Sanjay
    Jahan, Thierry
    Antonia, Scott
    Oulkhouir, Youssef
    Bautista, Yolanda
    Cornelissen, Robin
    Greillier, Laurent
    Grossi, Francesco
    Kowalski, Dariusz
    Rodriguez-Cid, Jeronimo
    Aanur, Praveen
    Oukessou, Abderrahim
    Baudelet, Christine
    Zalcman, Gerard
    [J]. LANCET, 2021, 397 (10272) : 375 - 386
  • [2] A Systematic Review of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
    Cao, Christopher Q.
    Yan, Tristan D.
    Bannon, Paul G.
    McCaughan, Brian C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (10) : 1692 - 1703
  • [3] Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural Mesothelioma
    Krug, Lee M.
    Pass, Harvey I.
    Rusch, Valerie W.
    Kindler, Hedy L.
    Sugarbaker, David J.
    rosenzweig, Kenneth E.
    Flores, Raja
    Friedberg, Joseph S.
    Pisters, Katherine
    Monberg, Matthew
    Obasaju, Coleman K.
    Vogelzang, Nicholas J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) : 3007 - 3013
  • [4] Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
    Liu, Jing
    Blake, Stephen J.
    Yong, Michelle C. R.
    Harjunpaa, Heidi
    Ngiow, Shin Foong
    Takeda, Kazuyoshi
    Young, Arabella
    O'Donnell, Jake S.
    Allen, Stacey
    Smyth, Mark J.
    Teng, Michele W. L.
    [J]. CANCER DISCOVERY, 2016, 6 (12) : 1382 - 1399
  • [5] Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
    Menzies, Alexander M.
    Amaria, Rodabe N.
    Rozeman, Elisa A.
    Huang, Alexander C.
    Tetzlaff, Michael T.
    van de Wiel, Bart A.
    Lo, Serigne
    Tarhini, Ahmad A.
    Burton, Elizabeth M.
    Pennington, Thomas E.
    Saw, Robyn P. M.
    Xu, Xiaowei
    Karakousis, Giorgos C.
    Ascierto, Paolo A.
    Spillane, Andrew J.
    van Akkooi, Alexander C. J.
    Davies, Michael A.
    Mitchell, Tara C.
    Tawbi, Hussein A.
    Scolyer, Richard A.
    Wargo, Jennifer A.
    Blank, Christian U.
    Long, Georgina V.
    [J]. NATURE MEDICINE, 2021, 27 (02) : 301 - +
  • [6] Nowak AK, 2020, LANCET ONCOL, V21, P1213, DOI 10.1016/S1470-2045(20)30462-9
  • [7] A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
    Popat, S.
    Curioni-Fontecedro, A.
    Dafni, U.
    Shah, R.
    O'Brien, M.
    Pope, A.
    Fisher, P.
    Spicer, J.
    Roy, A.
    Gilligan, D.
    Gautschi, O.
    Nadal, E.
    Janthur, W. D.
    Castro, R. Lopez
    Campelo, R. Garcia
    Rusakiewicz, S.
    Letovanec, I
    Polydoropoulou, V
    Roschitzki-Voser, H.
    Ruepp, B.
    Gasca-Ruchti, A.
    Peters, S.
    Stahel, R. A.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 (12) : 1734 - 1745
  • [8] Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).
    Spicer, Jonathan
    Wang, Changli
    Tanaka, Fumihiro
    Saylors, Gene Brian
    Chen, Ke-Neng
    Liberman, Moishe
    Vokes, Everett E.
    Girard, Nicolas
    Lu, Shun
    Provencio, Mariano
    Mitsudomi, Tetsuya
    Awad, Mark M.
    Felip, Enriqueta
    Forde, Patrick M.
    Swanson, Scott
    Brahmer, Julie R.
    Kerr, Keith
    Dorange, Cecile
    Cai, Junliang
    Broderick, Stephen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
1